Selective Conventional Transarterial Chemoembolization Using a Glass Membrane Emulsification Device in Hepatocellular Carcinoma: Multicenter Clinical Trial in Japan
Liver Cancer · 10.07.2026 · 1-11
DOI: 10.1159/000552424 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 10.07.2026. Verfasst von Toshihiro Tanaka und 16 weiteren Autor:innen. Beteiligte Einrichtung: Diagnostic and Interventional Radiology, Nara Medical University, Kashihara, Japan. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
The aim of the study was to evaluate the complete response (CR) rate achieved with selective conventional transarterial chemoembolization (cTACE) using a porous glass membrane emulsification device in hepatocellular carcinoma (HCC).
Methods
In a multicenter phase II trial (jRCTs052200095) conducted between January 2021 and June 2023, 50 patients with unresectable HCC (tumor diameter ≤5 cm; Child-Pugh A or B) were enrolled. An emulsion of epirubicin and ethiodized oil (Lipiodol) prepared using the emulsification device was injected into the tumor-feeding arteries, followed by embolization with gelatin sponge particles. The primary endpoint was the CR rate at 3 months post-treatment. Secondary endpoints included the CR rate at 1 month and the incidence of adverse events. Outcomes were compared with a historical control cohort from the JIVROSG-1302 study in exploratory analyses.
Results
Two patients were excluded after enrollment, leaving 48 patients who received cTACE (safety set). An additional 3 patients were excluded post-treatment, yielding 45 patients for efficacy analysis. The CR rate at both 1 month and 3 months was 97.8% (95% confidence interval: 88.2–99.9%). Serious adverse events (grade ≥3) included elevated AST in 50.0% of patients, elevated ALT in 29.2%, thrombocytopenia in 2.1%, and elevated ALP in 2.1%. The proportion of patients with deterioration in ALBI grade (≥1 grade increase) at 3 months was 17.8%. In exploratory analyses, CR rates were numerically higher than those observed in the historical control.
Conclusion
Selective cTACE using a W/O emulsion prepared with a glass membrane pumping emulsification device was associated with high short-term CR rates in patients with HCC, with an acceptable safety profile. These findings support further clinical investigation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Diagnostic and Interventional Radiology, Nara Medical University, Kashihara, Japan.
- Nara City Hospital, Sakurai, Japan.
- Nara Prefectural General Medical Center, Sakurai, Japan.
- Saiseikai-Chuwa Hospital, Sakurai, Japan.
- Institute for Clinical and Translational Science, Nara Medical University, Sakurai, Japan.
Zitieren
APA
Tanaka, T., Anai, H., Masada, T., Sueyoshi, S., Sato, T., Toyoda, S., Matsumoto, T., Chanoki, Y., Oshima, K., Shimizu, S., Irizato, M., Taiji, R., Minamiguchi, K., Kunichika, H., Kurakami, H., Ichihashi, S., & Nishiofuku, H. (2026). Selective Conventional Transarterial Chemoembolization Using a Glass Membrane Emulsification Device in Hepatocellular Carcinoma: Multicenter Clinical Trial in Japan. Liver Cancer, 1-11. https://doi.org/10.1159/000552424
Vancouver
Tanaka T, Anai H, Masada T, Sueyoshi S, Sato T, Toyoda S, et al. Selective Conventional Transarterial Chemoembolization Using a Glass Membrane Emulsification Device in Hepatocellular Carcinoma: Multicenter Clinical Trial in Japan. Liver Cancer. 2026:1-11. doi:10.1159/000552424
BibTeX
@article{Tanaka2026,
author = {Tanaka, Toshihiro and Anai, Hiroshi and Masada, Tetsuya and Sueyoshi, Satoru and Sato, Takeshi and Toyoda, Shohei and Matsumoto, Takeshi and Chanoki, Yuto and Oshima, Keisuke and Shimizu, Sho and Irizato, Mariko and Taiji, Ryosuke and Minamiguchi, Kiyoyuki and Kunichika, Hideki and Kurakami, Hiroyuki and Ichihashi, Shigeo and Nishiofuku, Hideyuki},
title = {Selective Conventional Transarterial Chemoembolization Using a Glass Membrane Emulsification Device in Hepatocellular Carcinoma: Multicenter Clinical Trial in Japan},
journal = {Liver Cancer},
year = {2026},
pages = {1--11},
doi = {10.1159/000552424}
}
EUVIMED